AU2023219770A1 - Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders - Google Patents

Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders Download PDF

Info

Publication number
AU2023219770A1
AU2023219770A1 AU2023219770A AU2023219770A AU2023219770A1 AU 2023219770 A1 AU2023219770 A1 AU 2023219770A1 AU 2023219770 A AU2023219770 A AU 2023219770A AU 2023219770 A AU2023219770 A AU 2023219770A AU 2023219770 A1 AU2023219770 A1 AU 2023219770A1
Authority
AU
Australia
Prior art keywords
csf
patient
activity
expression
neurodegenerative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023219770A
Other languages
English (en)
Inventor
Timothy Boyd
Ila JOSHI
Edwin ROCK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Partner Therapeutics Inc
Original Assignee
Partner Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Partner Therapeutics Inc filed Critical Partner Therapeutics Inc
Publication of AU2023219770A1 publication Critical patent/AU2023219770A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4703Regulators; Modulating activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2023219770A 2022-02-11 2023-02-10 Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders Pending AU2023219770A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263309220P 2022-02-11 2022-02-11
US63/309,220 2022-02-11
PCT/US2023/062374 WO2023154855A2 (en) 2022-02-11 2023-02-10 Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders

Publications (1)

Publication Number Publication Date
AU2023219770A1 true AU2023219770A1 (en) 2024-08-22

Family

ID=87565120

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023219770A Pending AU2023219770A1 (en) 2022-02-11 2023-02-10 Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders

Country Status (8)

Country Link
US (1) US20250134959A1 (https=)
EP (1) EP4475874A2 (https=)
JP (1) JP2025508308A (https=)
KR (1) KR20240147980A (https=)
CN (1) CN118660715A (https=)
AU (1) AU2023219770A1 (https=)
CA (1) CA3242855A1 (https=)
WO (1) WO2023154855A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023235795A2 (en) * 2022-06-01 2023-12-07 Partner Therapeutics, Inc. Granulocyte-macrophage colony-stimulating factor-based treatments for pulmonary or respiratory diseases or disorders
WO2025168003A1 (zh) * 2024-02-06 2025-08-14 上海市第四人民医院 一种治疗神经退行性疾病的药物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7785601B2 (en) * 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
JP2023514972A (ja) * 2020-02-12 2023-04-12 ザ スクリプス リサーチ インスティテュート 長時間作用型gm-csfおよび使用方法

Also Published As

Publication number Publication date
CN118660715A (zh) 2024-09-17
WO2023154855A2 (en) 2023-08-17
KR20240147980A (ko) 2024-10-10
CA3242855A1 (en) 2023-08-17
EP4475874A2 (en) 2024-12-18
JP2025508308A (ja) 2025-03-26
WO2023154855A3 (en) 2023-10-05
US20250134959A1 (en) 2025-05-01

Similar Documents

Publication Publication Date Title
Harari et al. Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis
KR100439289B1 (ko) 인터로이킨-18수용체단백질
EP4552699A2 (en) Albumin binding domain fusion proteins
US20250134959A1 (en) Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders
AU623698B2 (en) Macrophage-derived inflammatory mediator (mip-2)
KR20200015477A (ko) 신경 퇴행성 질환을 치료하기 위한 cd14 길항제 항체
US10695404B2 (en) Treatment of steroid-induced hyperglycemia with fibroblast growth factor (FGF) 1 analogs
ITRM940794A1 (it) Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130
CA2743394C (en) Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases
JP7678802B2 (ja) Siglec-9ECD融合分子及びその使用方法
WO2021063350A1 (zh) 一种融合蛋白及其应用
US20070149439A1 (en) Pituitary adenylate cyclase-activating polypeptide (PACAP) is an anti-mitogenic signal for selected neuronal precursors in vivo
US20250230210A1 (en) Long-acting granulocyte macrophage-colony stimulating factor
US20240361339A1 (en) Biomarkers for parkinson's disease
EP3917958A1 (en) Treatment of neurotoxicity and / or cytokine release syndrome
CN121002060A (zh) 犬il-13的犬抗体
CA3228064A1 (en) Gpc3-targeted antibody interferon .alpha. fusion protein and use thereof
CN118043672A (zh) 帕金森病的生物标志物
WO2023235795A2 (en) Granulocyte-macrophage colony-stimulating factor-based treatments for pulmonary or respiratory diseases or disorders
US20240182535A1 (en) Granulocyte macrophage-colony stimulating factor mutants
HK40015886B (en) Albumin binding domain fusion proteins
HK40015886A (en) Albumin binding domain fusion proteins